We have developed a conceptually new generation of non-peptidic HIV-1 protease inhibitors incorporating novel structural templates inspired by nature. This has resulted in protease inhibitors with exceptional potency and excellent pharmacological and drug-resistance profiles. The design of a stereochemically defined bis-tetrahydrofuran (bis-THF) scaffold followed by modifications to promote hydrogen bonding interactions with the backbone atoms of HIV-1 protease led to darunavir, the first clinically approved drug for treatment of drug resistant HIV. Subsequent X-ray crystal structure-based design efforts led us to create a range of exceptionally potent inhibitors incorporating other intriguing molecular templates possessing fused ring polycyclic ethers with multiple stereocenters. These structural templates are critical to inhibitors' exceptional potency and drug-like properties. Herein, we will highlight the synthetic strategies that provided access to these complex scaffolds in a stereoselective and optically active form, enabling our medicinal chemistry and drug development efforts.
Keyphrases
- antiretroviral therapy
- hiv positive
- drug resistant
- hiv testing
- hiv infected
- human immunodeficiency virus
- hiv aids
- hepatitis c virus
- men who have sex with men
- hiv infected patients
- multidrug resistant
- ionic liquid
- acinetobacter baumannii
- magnetic resonance
- high resolution
- anti inflammatory
- pseudomonas aeruginosa
- adverse drug